Last updated on July 2010

Curcumin in Rheumatoid Arthritis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Age ≥ 18 years; read and understand English
    Stable dose of non-steroidal anti-inflammatory agents (NSAID) for ≥ 2 weeks.
    Oral prednisone or equivalent ≤ 10 mg daily and stable dose for ≥ 2 weeks(and must be
    kept stable throughout the duration of the protocol).
    ESR > 20 mm/hr, or CRP > 0.8 mg/dl
    May be using any of the following DMARDs: methotrexate, sulfasalazine,
    hydroxychloroquine or leflunomide. If using any of these DMARDs must be using them
    for ≥ 12 weeks and stable dose for ≥ 4 weeks. If using other DMARD, or DMARD
    combinations, these additional or other DMARDs must be stopped for ≥ 4 weeks before
    baseline visit. May also participate if patient not on DMARD,
    Subjects must be diagnosed with rheumatoid arthritis based on the revised American
    College of Rheumatology criteria:Presence of > swollen and > 6 tender joint count (28
    joint count), and either ESR > 20 mm/hr or CRP > 0.8 mg/dl

You may not be eligible for this study if the following are true:

  • Acute medical conditions deemed as inappropriate by the investigators (acute heart
    failure, uncontrolled diabetes mellitus, uncontrolled hypertension)
    AST/ALT > 1.5 upper limit of normal (ULN)
    Serum creatinine > 1.6 mg/dl
    Hemoglobin/Hematocrit < 10.0 gram/dl/ 30.0
    Platelet count < 100,000
    Current use of warfarin (as there is a drug interaction between curcumin and
    warfarin).
    Currently on biologic therapy (must have stopped etanercept for ≥ 4 weeks or
    adalimumab or infliximab for ≥ 8 weeks at time of Time 1 visit),
    Women who are pregnant,
    Subjects who are taking digoxin, warfarin and/or heparin,
    Subjects with a history of antiphospholipid syndrome and other thrombophilic states,
    Subjects who have an INR >= 1.5 at baseline,
    Subjects with acute episode(s) of cholecystitis within the last 6 months,
    Subjects with active peptic ulcer disease within the last 6 weeks

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.